Immune checkpoint inhibitors

making immunotherapy a reality for the treatment of lung cancer

Research output: Contribution to journalArticle

Abstract

Despite the limited success of immunotherapies in solid malignancy, two human cancers, melanoma and renal cancer, have, for many years, responded to systemic administration of immune-targeted biologics and showed signals of response to certain therapeutic vaccines. These findings underpinned a long-held perception that melanoma and renal cancer were uniquely "immunogenic" but that virtually all other human cancers were not and thus would not respond to immune modulation. That notion has now been shattered by the significant and durable responses in non-small cell lung cancer induced by therapeutic treatment with antibodies blocking the PD-1 checkpoint. The immunotherapy success in lung cancer thus provides a gateway to development of treatments for multiple cancer types that were previously believed not accessible to immune-based therapies.

Original languageEnglish (US)
Pages (from-to)85-91
Number of pages7
JournalCancer immunology research
Volume1
Issue number2
DOIs
StatePublished - Aug 1 2013

Fingerprint

Immunotherapy
Lung Neoplasms
Kidney Neoplasms
Melanoma
Neoplasms
Therapeutics
Blocking Antibodies
Biological Products
Non-Small Cell Lung Carcinoma
Vaccines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{438c16fd08fe44139bb815274176b6bc,
title = "Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer",
abstract = "Despite the limited success of immunotherapies in solid malignancy, two human cancers, melanoma and renal cancer, have, for many years, responded to systemic administration of immune-targeted biologics and showed signals of response to certain therapeutic vaccines. These findings underpinned a long-held perception that melanoma and renal cancer were uniquely {"}immunogenic{"} but that virtually all other human cancers were not and thus would not respond to immune modulation. That notion has now been shattered by the significant and durable responses in non-small cell lung cancer induced by therapeutic treatment with antibodies blocking the PD-1 checkpoint. The immunotherapy success in lung cancer thus provides a gateway to development of treatments for multiple cancer types that were previously believed not accessible to immune-based therapies.",
author = "Julie Brahmer and Pardoll, {Andrew Mark}",
year = "2013",
month = "8",
day = "1",
doi = "10.1158/2326-6066.CIR-13-0078",
language = "English (US)",
volume = "1",
pages = "85--91",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Immune checkpoint inhibitors

T2 - making immunotherapy a reality for the treatment of lung cancer

AU - Brahmer, Julie

AU - Pardoll, Andrew Mark

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Despite the limited success of immunotherapies in solid malignancy, two human cancers, melanoma and renal cancer, have, for many years, responded to systemic administration of immune-targeted biologics and showed signals of response to certain therapeutic vaccines. These findings underpinned a long-held perception that melanoma and renal cancer were uniquely "immunogenic" but that virtually all other human cancers were not and thus would not respond to immune modulation. That notion has now been shattered by the significant and durable responses in non-small cell lung cancer induced by therapeutic treatment with antibodies blocking the PD-1 checkpoint. The immunotherapy success in lung cancer thus provides a gateway to development of treatments for multiple cancer types that were previously believed not accessible to immune-based therapies.

AB - Despite the limited success of immunotherapies in solid malignancy, two human cancers, melanoma and renal cancer, have, for many years, responded to systemic administration of immune-targeted biologics and showed signals of response to certain therapeutic vaccines. These findings underpinned a long-held perception that melanoma and renal cancer were uniquely "immunogenic" but that virtually all other human cancers were not and thus would not respond to immune modulation. That notion has now been shattered by the significant and durable responses in non-small cell lung cancer induced by therapeutic treatment with antibodies blocking the PD-1 checkpoint. The immunotherapy success in lung cancer thus provides a gateway to development of treatments for multiple cancer types that were previously believed not accessible to immune-based therapies.

UR - http://www.scopus.com/inward/record.url?scp=84892485531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892485531&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-13-0078

DO - 10.1158/2326-6066.CIR-13-0078

M3 - Article

VL - 1

SP - 85

EP - 91

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 2

ER -